Evidence map›Paper›PMID 41975505›Full record

ArticleJournal of experimental & clinical cancer research : CR2026

DNA base lesion-containing G-quadruplex mediates transcriptome reprogramming in EGFR-TKI resistance of non-small cell lung cancer.

Xinming Jing, Zheng Liu, Lujie Yang, Yanli Xiong, Shixun Li, Ruyi Hang, Xiao Yang, Xiaoyan Dai, Jiangyang Li, Jing Yang and 9 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Xinming Jing *Cancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Zheng Liu *Cancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Lujie Yang *Cancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Yanli XiongCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Shixun LiCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Ruyi HangCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Xiao YangCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Xiaoyan DaiCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Jiangyang LiCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Jing YangCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Yi ChengCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Ziqi JiangCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Huifen CaoInstitute of Genomics, School of Medicine, Huaqiao University, Xiamen, China.
Philipp KapranovState Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, China.
Qian ChenCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Dong WangCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China.
Wei GuoThoracic Surgery Department, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China. gyguowei@tmmu.edu.cn.
Zhou HuangCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China. ahuang_azhou@tmmu.edu.cn.
Mengxia LiCancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University, Chongqing, China. limengxia@tmmu.edu.cn.

Funding

National Natural Science Foundation of China 81871897National Natural Science Foundation of China 82002444National Natural Science Foundation of China 82203422National Natural Science Foundation of China 82303945Special Project for Enhancing Technological Innovation Capability of Third Military Medical University 2022XQN49the Postgraduate Research & Practice Innovation Program of Chongqing Provincethe Postgraduate Research & Practice Innovation Program of Chongqing Province CYB240289The Talent Innovation and Capacity Building Program (Organized Research) of the Army Medical Center of PLA ZXYZZKY07
6 · The paper itself

Abstract

backgroundCancer cells, such as non-small cell lung cancer (NSCLC) cells, exhibit remarkable phenotypic plasticity and undergo epigenetic reprogramming, characteristics that enable them to evade targeted therapies. However, how NSCLC cells use epigenetic regulatory mechanisms (including endogenous DNA base damage) to drive transcriptome reprogramming and develop resistance to EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy remains unclear.

methodsWe employed an integrated multi-omics approach in erlotinib-sensitive and resistant NSCLC cells, including genome-wide mapping of abasic sites (AP sites) via Single-Strand Break Mapping at Nucleotide Genome Level-AP (SSiNGLe-AP), characterization of binding landscapes of 8-Oxoguanine DNA Glycosylase 1 (OGG1), Apurinic/Apyrimidinic Endonuclease 1 (APE1), and genome-wide profiling of G-quadruplex (G4) structures by Cleavage Under Targets and Tagmentation sequencing (CUT&Tag-seq). Combined with RNA-seq and ATAC-seq analysis, we performed functional validation using overexpression, RNAi, qPCR, western blot, immunofluorescence, sphere formation, and flow cytometry. High-resolution microscopy revealed that oxidized base lesions and repair complexes orchestrated the spatiotemporal dynamics of G4 structures. Co-localization of G4 structures with CpG islands (CGIs) was assessed by Whole-Genome Bisulfite Sequencing (WGBS). Finally, the therapeutic relevance of targeting this pathway was evaluated using a mouse xenograft model treated with APE1 inhibitors.

resultsWe identified the DNA base lesion repair proteins OGG1 and APE1 as key mediators of transcriptional reprogramming that promote cancer cell plasticity and resistance to EGFR-TKIs. Mechanistically, genome-wide profiling revealed their dynamic redistribution to specific genomic loci in resistant cells. Beyond canonical repair, APE1 stabilizes G4 structures at the promoters of epithelial-mesenchymal transition (EMT) and stemness-associated genes, facilitating their transcriptional activation. This APE1-driven, G4-dependent transcriptional program occurs preferentially at hypomethylated CGIs, revealing a mechanism by which DNA secondary structures shape the epigenetic landscape to promote cellular plasticity.

conclusionOur study elucidates a novel pathway in which OGG1/APE1-mediated processing of oxidative damage orchestrates a G4-dependent transcriptional program to drive EMT and stemness in EGFR-TKI-resistant NSCLC. The therapeutic potential of targeting this axis is demonstrated by the efficacy of BER inhibitors in suppressing tumor growth in vivo, establishing APE1-G4 targeting as a promising anti-resistance strategy.

Indexed as

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmG-QuadruplexesLung NeoplasmsProtein Kinase InhibitorsTranscriptomeAnimalsCell Line, TumorDNA-(Apurinic or Apyrimidinic Site) LyaseErbB ReceptorsFemaleHumansMiceXenograft Model Antitumor AssaysDNA-(Apurinic or Apyrimidinic Site) LyaseEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsBase excision repairEGFR-TKI resistanceG-quadruplexPlasticity

Identifiers

PMID41975505
PMCPMC13185293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.